

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of inhibiting growth of a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary tumor a composition comprising taurolidine or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis, wherein said tumor is ovarian cancer.
2. - 4. (Cancelled)
5. (Previously Presented) The method of claim 1, wherein said composition is administered to directly contact the surface of a cell of said recurrent tumor.
6. (Currently Amended) The method of ~~claim 4~~ claim 1, wherein said composition is administered by intraperitoneal lavage.
7. (Currently Amended) The method of ~~claim 3~~ claim 1, wherein said composition is administered systematically.
8. (Previously Presented) The method of claim 7, wherein said composition is administered intravenously.
9. (Cancelled)
10. (Original) The method of claim 1, wherein said composition comprises taurolidine.
11. (Original) The method of claim 1, wherein said composition comprises a taurolidine derivative or metabolite.
12. (Original) The method of claim 1, further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.
13. (Currently Amended) A method of inhibiting growth of a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary

tumor a composition comprising taurultam or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis, wherein said tumor is ovarian cancer.

14. - 16. (Cancelled)

17. (Previously Presented) The method of claim 13, wherein said composition is administered to directly contact the surface of a cell of said recurrent tumor.

18. (Currently Amended) The method of ~~claim 16~~ claim 13, wherein said composition is administered by intraperitoneal lavage.

19. (Currently Amended) The method of ~~claim 15~~ claim 13, wherein said composition is administered systematically.

20. (Previously Presented) The method of claim 19, wherein said composition is administered intravenously.

21. (Cancelled)

22. (Original) The method of claim 13, wherein said composition comprises taurultam.

23. (Original) The method of claim 13, wherein said composition comprises a taurultam derivative or metabolite.

24. (Original) The method of claim 13, further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

25. - 77. (Cancelled)

78. (New) The method of claim 1, wherein said composition consists of taurolidine and a pharmaceutically acceptable excipient.

79. (New) The method of claim 1, wherein said composition consists of taurolidine, a chemotherapeutic agent, and a pharmaceutically acceptable excipient.

80. (New) The method of claim 79, wherein said chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

81. (New) The method of claim 13, wherein said composition consists of taurultam and a pharmaceutically acceptable excipient.

82. (New) The method of claim 1, wherein said taurolidine is administered prophylactically at the time of surgery of said primary tumor.

83. (New) The method of claim 13, wherein said composition consists of taurultam, a chemotherapeutic agent, and a pharmaceutically acceptable excipient.

84. (New) The method of claim 83, wherein said chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

85. (New) The method of claim 13, wherein said taurultam is administered prophylactically at the time of surgery of said primary tumor.